Armaceutica

A Phase 2a, multi-center, randomized, double-blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of pyronaridine as an Add-on therapy in adults with acute lymphoblastic leukemia and Acute Myeloid Leukemia. A Phase 2a clinical trial on up to n=200 male and female subjects aged 18 and over who were diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Subjects are randomized in approximately a 1:1 ratio to receive standard-of-care treatment plus either pyronaridine or placebo. Quality-of-life parameters are measured. Visits include physical examinations and blood draws for CBC and CMP.